Swing Therapeutics

Executive Summary

Swing Therapeutics is a San Francisco-based digital health company pioneering evidence-based, software-driven behavioral therapies for chronic conditions. Its flagship product, Stanza, is the first FDA-cleared digital behavioral therapy specifically designed for managing fibromyalgia symptoms, addressing a significant unmet need in rheumatology. By leveraging proprietary software to deliver cognitive-behavioral interventions, Swing aims to increase access to non-drug treatments and reduce reliance on pharmaceuticals. The company's focus on scalable, convenient therapies positions it well in the growing digital therapeutics market, particularly as healthcare systems seek cost-effective, non-invasive solutions for chronic pain management. With a strong regulatory milestone already achieved, Swing is poised to expand its platform to other chronic indications and pursue commercial partnerships to drive adoption.

Upcoming Catalysts (preview)

• Q1 2027Expansion into new chronic pain indications (e.g., chronic low back pain)50% success
• Q2 2026Strategic partnership with a major payer or employer for Stanza reimbursement60% success
• Q3 2026Series B or later funding round to support commercial scale-up70% success